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grouped by gender and age. The study was conducted
from the societal perspective using Year 1996–1999
prices, adjusted to year 2000 by CPI. Life expectancies
were adjusted for QOL using the Index of Well-Being.
Probabilities and prices were collected from the litera-
ture, the SEER program, National Vital Statistics, and
BLS. The model considered H. pylori reinfection and gas-
tric carcinogenesis risk over time. One-way sensitivity
analyses were conducted on critical or uncertain parame-
ters and threshold analyses on pivotal parameters. RE-
SULTS: The incremental cost-effectiveness ratio (ICE) for
pooled patients (both genders) decreases with age from
$3,612 per quality adjusted life year (QALY) saved at age
40–44 to the minimum of $200 (dominant) per QALY
saved at age 65–70. After age 70, the ICE increases with
age. Females have higher ICEs than males in every age
subgroup. The ICE was sensitive to discount rate, relative
risk of gastric cancer (GC) in H. pylori infected patients,
cost of treating GC, and cost of empiric antisecretory
therapy, but not to the reinfection rate or infection rate
of H. pylori, the change of the utility rate of GC and the
one-year utility of dyspepsia patient under empiric anti-
secretory therapy. CONCLUSIONS: Taking $50,000/
QALY as the societal ICE threshold, H. pylori screening
and eradication is cost-effective for both genders at any
age group, especially for male patients at older ages. Bet-
ter estimates are needed for certain key parameters such
as the relative risk reduction of GC with H. pylori eradi-
cation.
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OBJECTIVES: Meperidine/midazolam (M/M) and pro-
pofol (P) are clinically effective alternatives for sedation
during endoscopic procedures. Propofol has a higher ac-
quisition cost, but may be associated with cost savings
due to shorter duration of post-procedure care. The ob-
jective of this project was to compare the costs associated
with complex upper endoscopic procedures (ERCP/EUS)
in subjects who received either M/M or propofol.
METHODS: Subjects scheduled for ERCP/EUS were ran-
domized to receive M/M or P during the procedure. A
blinded observer assessed time to recovery using a stan-
dard 10-point postanesthesia recovery score (PARS) ev-
ery 15 minutes. Once a PARS score of 10 was reached,
the study terminated and the subject was discharged from
the recovery ward. The cost of drug (source: Redbook),
an anesthetist for the propofol group (source: Bureau of
Labor Statistics), recovery room personnel costs (source:
Bureau of Labor Statistics), and overhead costs were
compared from the institutional perspective. A sensitivity
analysis was performed by assuming generic drug, a
nurse anesthetist, and licensed practical nurse (LPN) care
in the recovery ward. RESULTS: 33 and 31 subjects were
randomized to receive M/M and P, respectively. There
were no significant differences detected between the
groups in age, gender, case severity, or procedure dura-
tion. P group subjects had a significantly shorter post-
procedure recovery time (19 minutes) compared with
M/M group subjects (71 minutes, p  0.001). Subjects in
the M/M group cost an average of $65 per case, while P
group subjects cost an average of $144 per case (p 
0.001). The sensitivity analysis resulted in an average
cost of $77 per case in the P group and $34 in the M/M
group (p  0.001). CONCLUSIONS: Subjects in the P
group had a significantly shorter post-procedure recovery
time but this did not result in cost savings compared with
subjects treated with M/M.
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OBJECTIVES: Treatment effects are often evaluated by
comparing groups in terms of the proportion of “re-
sponders”, i.e., patients who achieve some prospectively
defined outcome. In the absence of additional data, it is
assumed that responders in different treatment groups
achieve comparable benefits and therefore that the treat-
ment benefit is fully described by the responder rates.
This study compared the HRQOL changes of responders
in two treatment groups. METHODS: In two identical
randomized, double-blind, placebo-controlled studies
(S3BA3001; S3BA3002) in women evaluating 12 weeks
of treatment with alosetron 1mg BID, patients completed
the Irritable Bowel Syndrome Quality of Life Question-
naire (IBSQOL) at baseline and at the final treatment
visit. A patient was classified as a responder if she
achieved adequate relief of IBS pain and discomfort on at
least 2 of 4 weeks for all 3 months. This post-hoc analysis
compared responders from the two treatment groups in
terms of IBSQOL change from baseline scores at the final
visit using analysis of covariance. The analysis focused on
patients with diarrhea-predominant IBS. RESULTS: Our
analyses included 154 patients (96 alosetron and 58 pla-
cebo) in S3BA3001 and 172 (110 alosetron and 62 pla-
cebo) in S3BA3002. Compared with placebo responders,
those in the alosetron group had significantly higher (p 
.05) scores on 5 of 9 IBSQOL scales (sleep; energy; physi-
cal functioning, food and role-physical) in S3BA3001 and
on 4 scales (sleep, energy, food and social functioning) in
S3BA3002. CONCLUSIONS: Adequate relief responders
in the alosetron group experienced significantly greater
HRQOL improvements relative to placebo group re-
sponders. This suggests that treatment benefits may be
underestimated when described only in terms of the addi-
tional proportion of responders. Reporting HRQOL dif-
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ferences between responders in the treatment groups pro-
vides a more comprehensive characterization of the
treatment effect.
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BACKGROUND: Economic aspects are important when
assessing the overall benefit of a treatment strategy. The
number of investigations of these aspects are few within
the field of Crohn’s disease (CD). OBJECTIVE: To assess
the economic consequences, from a health care budget
perspective, of treating CD patients with budesonide CIR
(Entocort capsules) 6 mg per day as maintenance therapy
compared to no maintenance treatment (NMT). METHOD:
A validated decision-analytic model (Noble et al., 1998)
on the treatment of CD in Sweden was used. The model
used pooled patient data from randomised, double blind
trials of budesonide CIR capsules (n  90) versus placebo
(n  90) and covers a study period of one year. For
events not investigated in the clinical trials, literature and
panel data were used. Cost inputs for health care re-
sources were based on costs observed for 11 regional hos-
pitals in Sweden in year 1996. The analysis took into ac-
count costs for health care resources associated with
managing inactive and active phases of CD, e.g., diagnos-
tic and surgical procedures, physician visits, hospitalisa-
tions and drug consumption. Panel data and cost inputs
were tested in a sensitivity analysis. RESULT: Average
annual cost per patient was SEK 36,745 for budesonide
CIR capsules patients compared to SEK 38,130 for NMT
patients. With a Swedish prevalence between 13,000 to
18,000 patients this could mean annual savings of 18 to
25 million SEK (2–2.8 million USD). Stability of the re-
sults was confirmed when altering values on panel data
and cost inputs. CONCLUSION: Budesonide CIR capsules,
prolonging time in remission, is a cost-saving treatment
strategy for the treatment of Crohn’s disease in Sweden.
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OBJECTIVES: Helicobacter pylori (H.pylori) eradication
triple therapy with a combination of lansoprazole, amox-
icillin, and clarithromycin was approved in September
2000 in Japan. The objective of this analysis was to com-
pare the cost-effectiveness of this eradication therapy
with conventional H2RA therapy in Japan. METHODS:
We used decision analysis software to establish two
Markov models, one for gastric ulcers and the other for
duodenal ulcers. The model design was based on the Jap-
anese H. pylori eradication guideline and specialists opin-
ions. The model input data were derived mainly from a
literature review. The models predict the direct medical
costs, number of disease free days (DFDs) and cost per
DFD for five years. Sensitivity analyses were conducted
by varying the success rate and the probability of endo-
scopic relapse in symptomatic patients. The payer’s per-
spective was selected. RESULTS: According to the gastric
ulcer model, the expected total costs of eradication and
conventional therapies for an individual patient at the
end of five years would be 169,719 Yen and 390,921
Yen, respectively; the expected DFDs 1,454 days and
1,313 days, respectively; and the expected cost per DFD
117 Yen and 298 Yen, respectively. According to the
duodenal ulcer model, the expected total costs of the
eradication and conventional therapies would be 134,786
Yen and 324,689 Yen, respectively; the expected DFDs
1,503 days and 1,387 days, respectively; and the ex-
pected cost per DFD 90 Yen and 234 Yen, respectively.
The sensitivity analyses showed the results of baseline
analysis to be robust. CONCLUSIONS: We found that
this eradication therapy is less costly and more effective
than conventional therapy for the treatment of gastric
and duodenal ulcers in a Japanese medical setting. Thus,
eradication therapy is recommended for gastric and
duodenal ulcers from an economic as well as a clinical
viewpoint, in Japan.
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OBJECTIVE: To assess the economic outcome, from a
health care budget perspective, of treating Crohn’s dis-
ease (CD) patients with budesonide controlled ileal re-
lease (CIR) 6 mg per day as maintenance therapy com-
pared to no maintenance therapy (NMT). METHODS: A
validated decision-analytic model (Noble et al., 1998) on
the treatment of (CD) was used. The model was adjusted
to specifically depict CD patient management in Finland.
The analysis was based on pooled patient data from ran-
domised, double blind clinical trials comparing budes-
onide CIR (n  90) in maintenance therapy with placebo
(n  90). In accordance with the clinical trials the analy-
sis covered a study period of up to one year. The analysis
took into account clinical outcomes and consequences of
